Research programme: viral haemorrhagic fever - Emergent Biosolutions

Drug Profile

Research programme: viral haemorrhagic fever - Emergent Biosolutions

Alternative Names: Viral haemorrhagic fever therapeutics- Emergent Biosolutions

Latest Information Update: 31 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mapp Biopharmaceutical
  • Developer Emergent BioSolutions
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Viral haemorrhagic fevers

Most Recent Events

  • 13 May 2017 Early research in Viral haemorrhagic fevers in USA (unspecified route)
  • 13 Feb 2017 Emergent Biosolutions receives grant from Biomedical Advanced Research and Development Authority for viral haemorrhagic fever therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top